Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-15
    E.g., 2018-08-15

Articles

26771 items
12:22 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Incyte's Jakafi meets in Phase II for steroid-refractory GvHD

Incyte Corp. (NASDAQ:INCY) said Jakafi ruxolitinib in combination with corticosteroids met the primary endpoint in the U.S. Phase II REACH1 trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company plans to submit an sNDA...
12:18 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Merck KGaA reports Phase I response data for M7824 in HPV-associated cancer

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a Phase I trial of M7824 to treat advanced or metastatic HPV-associated malignancies, including cervical, anal and...
12:16 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Merck KGaA reports Phase I response data for M7824 in NSCLC

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a cohort of patients with advanced non-small cell lung cancer in a Phase I trial of M7824. In...
12:14 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Array reports Phase III OS data for encorafenib/binimetinib/Erbitux triple combo in mCRC

Array BioPharma Inc. (NASDAQ:ARRY) reported additional data from the safety lead-in portion of the open-label, international Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a one-year...
12:13 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Merck KGaA's tepotinib meets in two Phase Ib/II trials for advanced HCC

Merck KGaA (Xetra:MRK) said once-daily oral tepotinib (MSC2156119J) as first- and second-line treatment each met the primary endpoints in the Phase II portions of two open-label Phase Ib/II trials to treat advanced c-Met receptor tyrosine...
12:11 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Lundbeck, Takeda planning Japanese regulatory submission for vortioxetine

H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) plan to submit a regulatory application in Japan this year for Brintellix vortioxetine (Trintellix) to treat major depressive disorder (MDD) after the drug met...
11:57 AM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial...
11:57 AM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Novartis' infigratinib leads to 25.4% ORR in urothelial carcinoma patients

Data from 67 patients with previously treated advanced urothelial carcinoma with fibroblast growth factor (FGF) receptor 3 (FGFR3; CD333) alterations in an expansion cohort of an open-label, international Phase I trial showed that once-daily 125...
11:56 AM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Filgotinib meets in Phase II for psoriatic arthritis

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said in May that once-daily 200 mg oral filgotinib (GLPG0634, GS-6034) met the primary endpoint of improving the proportion of patients with a 20% improvement in...
11:55 AM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...

Pages